The Pharma Data

OCTOBER 12, 2021

Trial met primary endpoint. AZD7442 is the only long-acting antibody combination shown to both prevent and treat COVID-19. The trial recorded 18 events in the AZD7442 arm (18/407) and 37 in the placebo arm (37/415). The trial recorded 18 events in the AZD7442 arm (18/407) and 37 in the placebo arm (37/415).

Trials 52

Trials Development Antibody Radiology 52

The Pharma Data

MARCH 29, 2022

Evusheld significantly reduced the risk of developing symptomatic COVID-19 in PROVENT Phase III trial, with protection lasting at least six months Evusheld retains neutralising activity against the Omicron BA.2 1-3 Evusheld was generally well-tolerated in the trial. Evusheld was generally well-tolerated in the trials.

Antibody 52

Antibody In-Vivo Vaccination Vaccine 52

The Pharma Data

NOVEMBER 18, 2021

Six-months follow-up of prevention trial showed 83% reduced risk of symptomatic COVID-19, with no severe disease or deaths with AZD7442. Separate treatment trial showed 88% reduced risk of severe COVID-19 or death when treated within three days of symptom onset.

Trials 52

Trials Antibody In-Vitro Vaccination 52

The Pharma Data

JUNE 25, 2021

AstraZeneca today announced results from the STORM CHASER trial assessing the safety and efficacy of AZD7442, a long-acting antibody (LAAB) combination, for the prevention of symptomatic COVID-19 in participants recently exposed to the SARS-CoV-2 virus. The PROVENT trial will give us more clarity in this patient population.

Trials 52

Trials Antibody In-Vitro Medicine 52

The Pharma Data

MARCH 22, 2021

The AstraZeneca US Phase III trial of AZD1222 demonstrated statistically significant vaccine efficacy of 79% at preventing symptomatic COVID-19 and 100% efficacy at preventing severe disease and hospitalisation. The trial had a 2:1 randomisation of vaccine to placebo. The specific search for CVST found no events in this trial.

Trials 52

Trials Vaccination Vaccine Radiology 52

The Pharma Data

NOVEMBER 18, 2020

Eli Lilly and Company’s antibody therapeutic will be distributed as part of the federal government’s Operation Warp Speed. . 18, 2020 /PRNewswire/ — Tampa General Hospital provided the first monoclonal antibody treatment to a COVID-19 positive patient today. TAMPA, Fla.,

Antibody 40

Antibody Medicine Protein Radiology 40

The Pharma Data

MAY 16, 2021

Adjuvanted recombinant COVID-19 vaccine candidate triggered strong neutralizing antibody responses in all adult age groups. Overall, the vaccine candidate elicited strong neutralizing antibody levels that were comparable to those generated by natural infection, with higher levels observed in younger adults (18 to 59 years old).

Immune Response 52

Immune Response Vaccination Vaccine Trials 52

The Pharma Data

MARCH 24, 2021

Positive high-level results from the primary analysis of the Phase III trial of AZD1222 in the US have confirmed vaccine efficacy consistent with the pre-specified interim analysis announced on Monday 22 March 2021. The NIAID-supported COVID-19 Prevention Network (CoVPN) participated in the trial. D8110C00001 1.

Vaccination 52

Vaccination Vaccine Radiology Trials 52

pharmaphorum

MARCH 31, 2021

billion to buy targeted radioligand therapy Lu-PSMA-617 from Endocyte , shortly after encouraging results in a phase 2 prostate cancer trial. Meanwhile, Novartis has secured European approval for a subcutaneous formulation of the anti-CD20 antibody ofatumumab for relapsing forms of multiple sclerosis (RMS) under the Kesimpta brand name.

Licensing 98

Licensing Licensing Gene Therapy Sales 98

Delveinsight

DECEMBER 10, 2020

The full data from late-phase trials of AstraZeneca’s COVID-19 vaccine have pointed to the potential for AZD1222 to work after a single dose and limit asymptomatic cases; however, missed main questions regarding the efficacy of the candidate. In a pooled analysis of 11,636 participants enrolled in two separate clinical trials in the U.K.

Gene Therapy 52

Gene Therapy Gene Vaccination Vaccine 52

The Pharma Data

DECEMBER 23, 2020

Joseph Kim , President and CEO of INOVIO, said, “We are very pleased to share peer-reviewed Phase 1 clinical data for INO-4800 published in The Lancet’s EClinicalMedicine , and are grateful for the support of all participants and investigator staff involved in the clinical trial.” mg and 2.0 mg and 2.0 The 1.0

DNA 40

DNA Vaccine Vaccination Immune Response 40

Intouch Solutions

SEPTEMBER 27, 2024

With the theme “Shaping the Future of Anticancer Therapies,” ESMO 2024 saw record crowds and focused on advancements across immuno-oncology, antibody drug conjugates (ADCs) and numerous malignancies. We heard about monoclonal antibodies, bispecifics and antibody-drug conjugates, and many of these are being used in combination.

DNA 59

DNA Trials Antibody Marketing 59

The Pharma Data

APRIL 17, 2021

Biogen continues to evaluate the efficacy, safety and tolerability of natalizumab EID through the prospective NOVA trial ( NCT03689972 ) with initial results expected in 2021. Biogen currently has more than 25 MS clinical trials underway including research on considerations around COVID-19 vaccination for people with MS.

Clinical Trials 52

Clinical Trials Clinical Trials Trials Radiology 52

XTalks

JANUARY 19, 2024

Currently, several alpha particle emitters are being investigated in clinical trials. To specifically target cancer cells, alpha-emitting radionuclides are often attached to molecules that have a high affinity for cancer cells, such as antibodies or peptides (ligands). Guarnaschelli in the webinar. Contact our team of experts today.

DNA 66

DNA Radiology FDA Approval Development 66

XTalks

JUNE 12, 2023

Medtronic’s proactive stance towards R&D is evident from the over 230 clinical trials it conducted and the more than 200 regulatory approvals it received in the US, Europe, Japan and China in the 2022 fiscal year. The company reported an investment of $2.7

FDA Approval 98

FDA Approval Production Sales In-Vitro 98

The Pharma Data

OCTOBER 6, 2021

AstraZeneca has submitted a request to the US Food and Drug Administration (FDA) for an Juncture Use Authorization (EUA) for AZD7442, its long- production antibody (LAAB) combination, for prophylaxis of proper COVID-19. The trial accrued 25 cases of discriminating COVID-19 at the primary analysis. AZD7442 was well- let.

Antibody 52

Antibody In-Vitro Trials Development 52

XTalks

SEPTEMBER 14, 2020

By the end of August, the World Health Organization (WHO) counted 33 vaccine candidates in some stage of clinical trial evaluation. As of July, the company and its federal partner stated that it is on track to supply between 500 million to 1 billion doses a year at a dose of 100 µg now selected for their Phase III trial.

Vaccination 92

Vaccination Vaccine Antibody Life Science 92